Zentalis Pharmaceuticals Climbs in Debut After Expanded IPO
(Bloomberg) -- Zentalis Pharmaceuticals Inc., a clinical-stage cancer treatment developer, rose 29% in its trading debut after raising about $165 million in an initial public offering.
The company's shares, which surged as much as 50% from the $18 offer price, closed Friday at $23.20, giving the firm a market value of $798 million. Zentalis sold 9.18 million shares on Thursday at the top of a marketed range, after expanding the IPO from 7.65 million shares.
The listing by New York-based Zentalis was the second in the U.S. since Covid-19 was declared a pandemic. Chinese software company WiMi Hologram Cloud Inc. went public this week after downsizing its share sale to raise $26.1 million, down from its earlier target of $37.7 million.
IPOs in the U.S. had come to a halt after the pandemic triggered a global stock rout in mid March. Companies and advisers have been reluctant to launch a listing amid the extreme market volatility.
Along with software, biotech listings in the past year have been among the most reliable performers, in contrast to disappointing results for many higher-profile companies including Uber Technologies Inc. and Lyft Inc.
“Biotech, biopharma will be the sector that opens the IPO market back up and we will see more SPACs,” said Jordan Saxe, head of health-care listings at Nasdaq, referring to special purpose acquisition companies. “The mentality of the investors is much more long term versus a more short-term quarter-to-quarter view.”
Saxe estimates that 30 to 35 biotech companies will go public this year, raising about $3.5 billion, assuming social distancing aimed at curtailing the spread of the pandemic ends by June. Last year, 46 biotechnology companies completed their IPOs on U.S. exchanges and raised $5.46 billion, according to data compiled by Bloomberg.
Zentalis focuses on discovering and developing drugs that targets the fundamental biological pathways of cancers. Its oral treatment for breast cancer, in partnership with Pfizer Inc., is in clinical trials, according to its filing with the U.S. Securities and Exchange Commissions.
The offering was led by Morgan Stanley, Jefferies Financial Group Inc., SVB Leerink Holdings LLC and Guggenheim Securities LLC. Zentalis is trading on the Nasdaq Global Market under the symbol ZNTL.
©2020 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.